8. Hasenburg A, Spätling L. Vorzeitige Wehentätigkeit - Ursachen und Therapiemöglichkeiten. TW Gynäkologie 1996; 9:

Transkript

1 Schriftenverzeichnis Originalarbeiten 1. Matschke, R.G., Hasenburg, A. Plath, P.: Zur Wertigkeit der 40 Hz MLR in der pädaudiologischen Diagnostik. Arch. Otorhinolaryngol. Suppl II, , Hasenburg A, Sehnert W, Grothey A. clinical course and outcome of artificially ventilated patients of an Internal care unit. Herz Kreislauf 1992; 24(4): Hasenburg A, Behrens C, Fallenstein F, Spätling L. Evaluation of preterm labor using 4- channel tocography. Arch Gynecol Obstet 1993; 254(1-4): Hasenburg A, Jaspers V, Siegmund Schultze E, Spätling L. Fatal amniotic-fluid embolism 20 hours after secondary cesarean-section. Der Gynäkologe 1994; 27(5): Spätling L, Danders R, Behrens C, Hasenburg A, Fallenstein F. The meaning of the origin of labor on the progress of delivery and gestational-age. Zeitschrift fur Geburtshilfe und Perinatologie 1994; 198(5-6): Spätling L, Fallenstein F, Danders R, Hasenburg A. External 4-channel tocography during delivery. Int J Gynecol Obstet 1994; 46(3): IF 1, Heber, G., Hasenburg, A., Jaspers, V., Spätling., L.: Methämoglobinämie beim Neugeborenen durch Prilocain verursacht? - Eine Falldarstellung. Zentralbl. Gynäkol. 117, , Hasenburg A, Spätling L. Vorzeitige Wehentätigkeit - Ursachen und Therapiemöglichkeiten. TW Gynäkologie 1996; 9: Fallenstein F, Hasenburg A, Steffens J, Spätling L, Quakernack K. Four-channel tocography in uneventful pregnancy - A longitudinal study with primi- and multiparas. Geburtshilfe und Frauenheilkunde 1997; 57(12): Grothey A, Hasenburg A, Philippou S, Voigtmann R. Prognostic relevance of microvessel density (MVD) in primary human breast cancer and lymph node metastases. European Journal of Cancer 1997; 33: IF 1, Spätling, L., Hasenburg, A.: Fruchtwasserembolie. Gynäkologe 1997(30), Spätling L, Behrens C, Hasenburg A, Fallenstein F. External four channel tocography in preterm labor. First results. Journal of Perinatal Medicine 1997; 25(1): IF 1, Spätling L, Hasenburg A. Fruchtwasserembolie. Der Gynäkologe 1997; 10: Tong XW, Agoulnik I, Blankenburg K, Contant CF, Hasenburg A, Runnebaum IB, Stickeler E, Kaplan AL, Woo SLC, Kieback DG. Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy. Anticancer Research 1997; 17(2A): Levy, T., Agoulnik, I., Atkinson, E.N., Tong, X.-W., Gause, H.M., Hasenburg, A., Runnebaum, I.B., Stickeler, E., Möbius, V.J., Kaplan, A.L., Kieback, D.G.: Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients. Anticancer Res. 17, 1-5, 1997

2 16. Grothey A, Duppe J, Hasenburg A, Voigtmann R. The use of alternative medicine in oncological patients. Deutsche Medizinische Wochenschrift 1998; 123(31-32): Hasenburg A, Soldan C, Behrens C, Fallenstein F, Spätling L, Quakernack K. Registration of fetal movement by four-channel-tocography. Zeitschrift fur Geburtshilfe und Neonatologie 1998; 202(3): Kudelka AP, Hasenburg A, Verschraegen CF, Edwards CL, Meyers CA, Varma D, Freedman RS, Forman A, Conrad CA, Grove W, Grothey A, Kavanagh JJ. Phase II study of i.v. Cl-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anti-Cancer Drugs 1998; 9(5): Levy T, Agoulnik I, Atkinson EN, Tong XW, Gause HM, Hasenburg A, Runnebaum I, Stickeler E, Mobus VJ, Kaplan AL, Kieback DG. Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients. Anticancer Research 1998; 18(3A): Tong XW, Engehausen DG, Freund CTF, Agoulnik I, Guo ZS, Oehler MK, Kim TE, Hasenburg A, Contant CF, Woo SLC, Kieback DG. The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter. Anticancer Research 1998; 18(2A): Tong XW, Engehausen DG, Kaufman RH, Agoulnik I, Contant C, Freund CTF, Oehler MK, Kim TE, Hasenburg A, Woo SLC, Kieback DG. Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy. Anticancer Research 1998; 18(2A): Tong XW, Shine DH, Agoulnik I, Freund CTF, Hasenburg A, Aguilar-Cordova E, Woo SLC, Kieback DG. Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents. Anticancer Research 1998; 18(5A): Hasenburg A, Ledet SC, Ardaman T, Levy T, Kieback DG. Evaluation of lymph nodes in squamous cell carcinoma of the cervix: touch imprint cytology versus frozen section histology. International Journal of Gynecological Cancer 1999; 9(4): Hasenburg A, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Kieback CC, Kaplan AL, Kaufman RH, Ramzy I, Aguilar-Cordova E, Kieback DG. Thymidine kinase (TK) gene therapy of solid tumors: Valacyclovir facilitates outpatient treatment. Anticancer Research 1999; 19(3B): Kieback DG, Hasenburg A, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Kaplan AL, Kaufman RH, Ramzy I, Aguilar-Cordova E. Thymidine kinase gene therapy in ovarian cancer. European Journal of Cancer 1999; 35: Tong XW, Engehausen DG, Freund CTF, Agoulnik I, Oehler MK, Kim TE, Hasenburg A, Guo ZS, Contant CF, Woo SLC, Kieback DG. Comparison of long-term survival of cytomegalovirus promoter versus rous sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer. Hybridoma 1999; 18(1): Hasenburg A, Grothey A, Jaspers V, Gitsch G, Spätling L. Breast size as risk factor for tumor size at diagnosis. Anticancer Research 2000; 20(3B): Hasenburg A, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Kieback CC, Kaplan A, Kaufman RH, Ramzy I, Aguilar-Cordova E, Kieback DG. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Therapy 2000; 7(6):

3 29. Harter M, Reuter K, Aschenbrenner A, Schretzmann B, Marschner N, Hasenburg A, Weis J. Psychiatric disorders and associated factors in cancer: results of an interview study with patients in inpatient, rehabilitation and outpatient treatment. European Journal of Cancer 2001; 37(11): Hasenburg A, Behrens C, Fallenstein F, Spätling L. Four-channel tocography in uneventful pregnancies: A prospective study in primigravidas and multigravidas. Journal of the Society for Gynecologic Investigation 2001; 8(1): Hasenburg A, Tong XW, Fischer DC, Rojas-Martinez A, Nyberg-Hoffman C, Kaplan AL, Kaufman RH, Ramzy I, Aguilar-Cordova E, Kieback DG. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecologic Oncology 2001; 83(3): You ZB, Fischer DC, Tong XW, Hasenburg A, Aguilar-Cordova E, Kieback DG. Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Therapy 2001; 8(3): Hasenburg A, Fischer DC, Tong XW, Rojas-Martinez A, Kaufman RH, Ramzy I, Kohlberger P, Orlowska-Volk M, Aguilar-Cordova E, Kieback DG. Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: Expression of coxsackie-adenovirus receptor and integrins alpha v beta 3 and alpha v beta 5. Journal of the Society for Gynecologic Investigation 2002; 9(3): Hasenburg A, Fischer DC, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Orlowska-Volk M, Kohlberger P, Kaufman RH, Ramzy I, Aguilar-Cordova E, Kieback DG. Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. International Journal of Gynecological Cancer 2002; 12(1): Hasenburg A, Salama JK, Van TJ, Amosson C, Chiu JK, Kieback DG. Evaluation of patients after extraperitoneal lymph node dissection and subsequent radiotherapy for cervical cancer. Gynecologic Oncology 2002; 84(2): Hasenburg A, Waterman D. Inkontinenz, Sexualität und Lebensqualität. Z f Physiotherapeuten 2002; 54: Hasenburg A, Watermann D. Sexualität und Lebensqualität bei Frauen mit ungewolltem Harnverlust. Praktische Gynäkologie 2002; 6: Waterman D, Hasenburg A. Physiologie und Pathophysiologie von Harnspeicherung und Entleerung: Neue Ansätze zum Verständnis eines multifaktoriellen Systems. Z f Physiotherapeuten 2002; 54: Waterman D, Hasenburg A. Das spannungsfreie Vaginalband: Ein neues operatives Verfahren zur Therapie der weiblichen Stress-Harninkontinenz. Z f Physiotherapeuten 2002; 54: Watermann DO, Einert A, Ehritt-Braun C, Hasenburg A, Kieback DG. Experience with the advanced breast biopsy instrumentation (ABBI) system. Anticancer Research 2002; 22(5): Hasenburg A. Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: Expression of coxsackie-adenovirus receptor and integrins alpha v beta 3 and alpha v beta 5 (vol 9, 174, 2002). Journal of the Society for Gynecologic Investigation 2003; 10(1): 58.

4 42. Hasenburg A, Bäuerle M, Waterman D, Wurstlein R, Moberg K, Kleiber S, Grab D, Kieback DG. European experience with a novel noninvasive sensor for intra-amniotic or extraamniotic evaluation of fetal oxygen saturation. Journal of the Society for Gynecologic Investigation 2003; 10(6): Kieback DG, Einzmann T, Labinsky E, Fischer DC, Niebergall H, Hasenburg A. Aggressive management of recurrent ovarian cancer the challenge of individualizing cancer therapy illustrated by a case report. Onkologie 2004; 27(4): Denschlag D, Gabriel B, Mueller-Lantzsch C, Tempfer C, Henne K, Gitsch G, Hasenburg A. Evaluation of patients after extraperitoneal lymph node dissection for cervical cancer. Gynecologic Oncology 2005; 96(3): Gropp M, Harter P, Canzler U, Richter B, Jackisch C, Hasenburg A, Burges A, Loibl S, Hahmann M, du Bois A. Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO Organkommission Ovar and the AGO ovarian cancer study group (AGO-OVAR). European Journal of Cancer Suppl 2005; 3(2): Hasenburg A, Waterman D, Orlowska-Volk M, Gitsch G. Pseudomyxoma peritonei. European Clinics in Obstetrics and Gynaecology 2005; 1: Menge S, Gitsch G, Hasenburg A. Intramural pregnancy in a 33-year-old gravida II/para I after previous cesarean section. Geburtshilfe und Frauenheilkunde 2005; 65(2): Müller-Lantzsch C, Watermann D, Orlowska-Volk M, Gitsch G, Hasenburg A. Multiple recurrent pseudomyxoma peritonei: The challenge of an individual therapy. Geburtshilfe und Frauenheilkunde 2005; 65(4): Pfisterer J, Harter P, Canzler U, Richter B, Jackisch C, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Du Bois A, Comm AO, Grp AOCS. The role of surgery in recurrent ovarian cancer. International Journal of Gynecological Cancer 2005; 15: Watermann DO, Földi M, Hanjalic-Beck A, Hasenburg A, Lughausen A, Prompeler H, Gitsch G, Stickeler E. Three-dimensional ultrasound for the assessment of breast lesions. Ultrasound in Obstetrics and Gynecology 2005; 25(6): Watermann DO, Gabriel B, Jäger M, Orlowska-Volk M, Hasenburg A, zur Hausen A, Gitsch G, Stickeler E. Specific induction of pp125 focal adhesion kinase in human breast cancer. British Journal of Cancer 2005; 93(6): Watermann DO, Stickeler E, Denschlag D, Henne K, Hasenburg A. Breast cancer in elderly women - Analysis of tumor stage and treatment modalities. Geburtshilfe und Frauenheilkunde 2005; 65(2): Schmalfeldt, B., du Bois, A.., Burges, A., Emons, G., Fink D., Gropp M., Hasenburg A., Jäger W., Kimmig R., Kiechle M., Kommoss F., Kreienberg R., Kuhn W., Lück H.-J, Meier W., Münstedt K., Ortmann O., Pfisterer J., Richter B., Runnebaum I., Schröder W., Sehouli J., Tanner B., Wagner U., Weis J.: Diagnostik und Therapie maligner Ovarialtumoren 2005: Die Empfehlungen der Kommission Ovar der AGO: Zentralbl Gynakol 2006(128), Gabriel B, Fischer DC, Orlowska-Volk M, zur Hausen A, Schule R, Muller JM, Hasenburg A. Expression of the transcriptional coregulator FHL2 in human breast cancer: A clinicopathologic study. Journal of the Society for Gynecologic Investigation 2006; 13(1):

5 55. Gabriel B, zur Hausen A, Stickeler E, Dietz C, Gitsch G, Fischer DC, Bouda J, Tempfer C, Hasenburg A. Weak expression of focal adhesion kinase (pp125fak) in patients with cervical cancer is associated with poor disease outcome. Clinical Cancer Research 2006; 12(8): Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schroder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee, AGO ovarian vancer study group. Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Annals of surgical oncology 2006; 13(12): Watermann, D., Sauerbrei, W., Denschlag, D., Hasenburg, A., Hörig, K., Orlowska-Volk, M., Stickeler, E.: A diagnostic score for the ultrasound determination of lymph node metastasis in breast cancer patients: Ultraschall Med 2006 (27), Lassmann S, Shen Y, Jütting U, Whiele P, Walch A, Gitsch G, Hasenburg A, Werner M. Aurora-A STK15 expression predicts the response to adjuvant chemotherapy of patients with FIGO stage III epithelial ovarian cancers and represents a therapeutic target per se. Pathology- Research and Practice 2007; 203(5): Lassmann S, Shen Y, Jütting U, Wiehle P, Walch A, Gitsch G, Hasenburg A, Werner M. Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clinical Cancer Research 2007; 13(14): Lassmann, S., Shen, Y., Jütting, U., Wiehle, P., Walch, A., Gitsch, G., Hasenburg, A., Werner, M.: Aurora-a is a predictive marker for stage III epithelial ovarian cancer. Verhandlungen der Deutschen Gesellschaft für Pathologie. 2007; 91: Scheidt CE, Waller N, Wangler J, Hasenburg A. Trauerverarbeitung nach Prä- und Perinatalverlust, Prävalenz, klinisches Bild und Behandlung - eine Übersicht über den aktuellen Forschungsstand. Psychotherapie Psychosomatik Medizinische Psychologie 2007; 57: Stumpf M, Orlowska-Volk M, Hasenburg A, Gabriel B. Primary ovarian rhabdomyosarcoma in a 42-year-old woman: A case report. Geburtshilfe und Frauenheilkunde 2007; 67(4): Földi M, Vogel B, Helmes A, Hasenburg A, Gitsch G. Agreement between the desired and experienced role in the decision process in patients with mammacarcinoma. Geburtshilfe und Frauenheilkunde 2008; 68: 138-S. 64. Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen H, Weyer G, Hasenburg A. Bone effects of exemestane versus tamoxifen within the TEAM trial: Results of a prospective randomized bone substudy. Journal of Clinical Oncology 2008; 26(15). 65. Kieback DG, Harbeck N, Bauer W, Hadji P, Weyers G, Hasenburg A. Endometrial safety of cross-over treatment with tamoxifen followed by exemestane. European Journal of Cancer Suppl 2008; 6(7): Markert S, Lassmann S, Gabriel B, Klar M, Werner M, Gitsch G, Kratz F, Hasenburg A. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Research 2008; 28(6A): Stumpf M, Lassmann S, Werner M, Hasenburg A. Aurora-A/STK 15 as a new marker to reaction's evaluation of adjunctive therapy in advanced ovarian carcinoma. Geburtshilfe und Frauenheilkunde 2008; 68: 71.

6 68. Scheidt, C.E., Kunze, M., Wangler, J., Klar, M., Waller, N., Hasenburg, A.: Psychische Folgen eines Früh- und Spätabortes in der Folgeschwangerschaft eine Pilotuntersuchung. Psychotherapie Psychosomatik Medizinische Psychologie 2008; 58: Vogel BA, Helmes AW, Hasenburg A. Concordance between patients' desired and actual decision-making roles in breast cancer care. Psycho-Oncology 2008; 17(2): Bartlett JMS, Brookes C, Robson T, van de Velde CH, Billingham LJ, Campbell FM, Quintayo MA, Lyttle N, Hasenburg A, Hille ETM, Kieback D, Putter H, Markopoulos C, Meershoek-Klein-Kranenbarg E, Paridaens R, Seynaeve C, Mallon EA, Rea DW. The TEAM trial pathology study identifies potential prognostic and predictive biomarker models for postmenopausal patients treated with endocrine therapy. Cancer Research 2009; 69(24): Bartlett JMS, Brookes CL, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ETM, Kay C, Kieback D, Markopoulos C, Kranenbarg EMK, Mallon EA, Paridaens R, Robson T, Seynaeve C, van de Velde CJH, Rea D. A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen. Cancer Research 2009; 69(2): Bartlett JMS, Rimm D, Brookes CL, Dolled-Filhart M, Robson T, van de Velde CH, Billingham LJ, Campbell FM, Hasenburg A, Hille ETM, Kieback D, Putter H, Markopoulos C, Christiansen J, Gustavson M, Mallon EA, Kranenburg EMK, Parideans R, Seynaeve C, Rea DW. Preliminary comparison between AQUA and centralised ER/PgR analysis within the TEAM pathology study. Cancer Research 2009; 69(24): 660s-1s. 73. El Khalfaoui K, Oskay-Ozcelik G, Richter R, Pietzner K, Harter P, Munstedt K, Mahner S, Hasenburg A, Wimberger P, Sehouli J. Prognostic factors in ovarian cancer patients with brain metastases: results of a german multicenter study. Journal of Clinical Oncology 2009; 27(15). 74. Gabriel B, Hasenburg A, Waizenegger M, Orlowska-Volk M, Stickeler E, zur Hausen A. Expression of focal adhesion kinase (FAK) in patients with endometrial cancer a clinicopothologic study. International Journal of Gynecological Cancer 2009; 19(7): Hadji P, Ziller M, Kieback D, Dornoff W, Tessen HW, Kuck J, Hasenburg A. Bone effects of exemestane vs. tamoxifen within the TEAM trial: results of a prospective randomized bone sub study. Cancer Research 2009; 69(2): Hadji P, Ziller M, Kieback DG, Menschik T, Kalder M, Kuck J, Hasenburg A. The effect of exemestane or tamoxifen on markers of bone turnover: results of a german sub-study of the tamoxifen exemestane adjuvant multicentre (TEAM) trial. Breast 2009; 18(3): Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, Hasenburg A, Burges A, Loibl S, Meier W, Huober J, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, du Bois A. Surgery for recurrent ovarian cancer: Role of peritoneal carcinomatosis: Exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Annals of Surgical Oncology 2009; 16(5): Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Kieback D, Asmar L, Smeets J, Urbanski R, Bartlett JMS, van de Velde CJH. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase Ill trial in hormone sensitive postmenopausal early breast cancer. Cancer Research 2009; 69(2): 67.

7 79. Pietzner K, El Khalfaoui K, Oskay-Ozcelik G, Richter R, Harter P, Munstedt K, Mahner S, Hasenburg A, Wimberger P, Sehouli J. Platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. British Journal of Cancer Suppl 2009; 7(2): Rea D, Hasenburg A, Seynaeve C, Jones SE, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Asnar L, Urbanski R, van de Velde CH, Bartlett JMS, Smeets J, Kieback DG. Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: The TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer. Cancer Research 2009; 69(24): Sehouli J, Harter P, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Polcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A, OVAR AKOA, Austria A, MITO, NOGGO. Prospective validation of a predictive score for complete tumor resection in recurrent ovarian cancer (ROC): an intergroup study of AGO kommission OVAR, AGO-OVAR, AGO Austria, MITO and NOGGO. European Journal of Cancer Suppl 2009; 7(2): Stickeler E, Klar M, Watermann D, Geibel A, Foldi M, Hasenburg A, Gitsch G. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Research and Treatment 2009; 117(3): Stumpf M, Hasenburg A, Riener MO, Jutting U, Wang C, Shen Y, Orlowska-Volk M, Fisch P, Wang Z, Gitsch G, Werner M, Lassmann S. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. British Journal of Cancer 2009; 101(9): van de Velde C, Seynaeve C, Hasenburg A, Rea D, Vannetzel JM, Paridaens R, Markopoulos C, Smeets J, Nortier JWR, Jones SE. Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. British Journal of Cancer Suppl 2009; 7(3): van Nes JGH, Seynaeve C, Jones S, Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Markopoulos C, Kranenbarg WMMK, van de Velde CJH. Patterns of care in postmenopausal early breast cancer patients participating in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study: variations in locoregional therapy between different countries. British Journal of Cancer Suppl 2009; 7(2): Hadji P, Asmar L, van Nes J, Menschik T, Hasenburg A, Kuck J, Nortier H, Jones S, van De Velde C, Ziller M. Effects of exemestane or tamoxifen on bone health within the tamoxifen exemestane adjuvant multinational (Team) trial: A meta-analysis. Annals of Oncology 2010; 21: Hasenburg A, van de Velde CJH, Seynaeve C, Rea DW, Vannetzel J, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Jones SE. Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer. British Journal of Cancer Suppl 2010; 8(3): Kieback DG, Harbeck N, Bauer W, Hadji P, Weyer G, Menschik T, Hasenburg A. Endometrial effects of exemestane compared to tamoxifen within the tamoxifen exemestane adjuvant multicenter (TEAM) trial: Results of a prospective gynecological ultrasound substudy. Gynecologic Oncology 2010; 119(3):

8 89. Nortier H, Hille E, Rea D, Seynaeve C, Hasenburg A, Vannetzel J, Dirix L, Markopoulos C, van de Velde C, Jones S. Distant Recurrences at median of 5-years among postmenopausal women with hormone receptor-positive early breast cancer treated on the team trial of adjuvant endocrine therapy. Annals of Oncology 2010; 21: Reuter K, Scholl I, Sillem M, Hasenburg A, Harter M. Implementation and benefits of psychooncological group interventions in german breast centers: A pilot study on supportive-expressive group therapy for women with primary breast cancer. Breast care 2010; 5(2): Sehouli J, Pietzner K, Harter P, Munstedt K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling KJ, Richter R, El Khalfaoui K, Oskay-Ozcelik G. Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a german multicenter study. Annals of Oncology 2010; 21(11): Nes, J.G., Seynaeve, C., Jones, S., Markopoulo, C., Putter, H., van de Velde, C.J., Hasenburg, A., Rea, D.W., Vannetzel, J.M., Dirix, L., Hozumi, Y., Kerin, M.J., Kieback, D.G., Meershoek-Klein Kranenbarg, W.M., Hille, E.T., Nortier, J.W., Tamoxifen and exemestane adjuvant multinational (TEAM) trialists.: Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. Br J Surg 2010; 97(5):671-9, 93. Bartlett AI, Starcyznski J, Robson T, MacLellan A, Campbell FM, van de Vekle CJH, Hasenburg A, Markopoulos C, Seynaeve C, Rea D, Bartlett JMS. Heterogeneous HER2 gene amplification impact on patient outcome and a clinically relevant definition. American Journal of Clinical Pathology 2011; 136(2): Bartlett JMS, Brookes CL, Robson T, van de Velde CJH, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ETM, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EMK, Mallon EA, Dirix L, Seynaeve C, Rea D. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: A prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. Journal of Clinical Oncology 2011; 29(12): Bossart M, Beussel S, Hadji P, Hasenburg A. Early breast cancer-quality of life after switching from tamoxifen to exemestane results of a non-interventional study. Geburtshilfe und Frauenheilkunde 2011; 71(10): Eckes J, Schmah O, Siebers JW, Groh U, Zschiedrich S, Rautenberg B, Hasenburg A, Jansen M, Hug MJ, Winkler K, Putz G. Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial). BMC Cancer 2011; Foldi M, Hanjalic-Beck A, Klar M, Seybold A, Mayer S, Saueressig U, Hasenburg A, Stickeler E, Waterman D. Video Sequence Compared to Conventional Freeze Image Documentation: A way to improve the sonographic assessment of breast lesions? Ultraschall in der Medizin 2011; 32(5): Hadji P, Asmar L, van Nes J, Menschik T, Hasenburg A, Kuck J, Nortier JWR, van de Vekle CJH, Jones S, Ziller M. The effect of exemestane and tamoxifen on bone health within the tamoxifen exemestane adjuvant multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. Journal of Cancer Research and Clinical Oncology 2011; 137: Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Polcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A. Prospective validation study

9 of a predictive score for operability of recurrent ovarian cancer the multicenter intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. International Journal of Gynecological Cancer 2011; 21(2): Hasenburg A, Amant F, Aerts L, Pascal A, Achimas-Cadariu P, Kesic V, Psycho-oncology structure and profiles of european centers treating patients with gynecological cancer. International Journal of Gynecological Cancer 2011; 21(9): Kieback DG, Hadji P, Menschik T, Hasenburg A, Tams J, Ziller M. Increased progressionfree and overall survival in patients with breast cancer with menopausal symptoms or arthralgia/myalgia during adjuvant treatment with exemestane or tamoxifen: Results of the German TEAM trial. Journal of Clinical Oncology 2011; 29(15) Markopoulos C, van de Water W, Putter H, Seynaeve C, Hasenburg A, Rea D, Vannetzel JM, Paridaens R, van de Velde CJH, Jones S. Age specific competing mortality in breast cancer patients - a TEAM study analysis. European Journal of Cancer 2011; 47: Schmah O, Eckes J, Groh U, Siebers JW, Zschiedrich S, Rautenberg B, Hasenburg A, Hug MJ, Winkler K, Putz G. Kinetic targeting: A new approach to reduce toxicities during nanoparticle (liposomal doxorubicin) based chemotherapy in early breast cancer (CARL Trial). Breast 2011; 20: van de Velde CJH, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ETM, Kieback DG, Asmar L, Smeets J, Nortier JWR, Hadji P, Bartlett JMS, Jones SE. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011; 377(9762): van de Water W, Hille ETM, Hadji P, Markopoulos C, Seynaeve C, Hasenburg A, Dirix L, Rea D, Jones SE, van de Velde CJH. Specific adverse events and outcome in hormone receptor positive breast cancer patients on endocrine therapy - a TEAM study analysis. European Journal of Cancer 2011; 47: Bartlett JMS, Bloom KJ, Robson T, Lawton TJ, Van de Velde CJH, Ross DT, Seitz RS, Beck RA, Hasenburg A, Kieback DG, Putter H, Markopoulos C, Dirix LY, Seynaeve CM, Rea D. Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the TEAM pathology study. Journal of Clinical Oncology 2012; 30(15) Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburg A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, Wagner U. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Annals of Oncology 2012; 23(9): Beussel S, Hasenburg A, Bogatyreva L, Hauschke D, Werner M, Lassmann S. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma. Journal of clinical pathology 2012; 65(1): Bossart M, Becker M, Hadji P, Kieback DG, Hasenburg A. Compliance, analgesic use and side-effect protection within a german cohort of the TEAM trial. Anticancer Research 2012; 32(9): Bossart M, Hadji P, Kieback D, Hasenburg A. The german cohort of the TEAM trial: Does prior chemotherapy affect the efficacy of endocrine therapy? European Journal of Cancer 2012; 48: Christiansen J, Bartlett JMS, Gustavson M, Rimm D, Robson T, Van de Velde CJH, Hasenburg A, Kieback DG, Putter H, Markopoulos C, Dirix LY, Seynaeve CM, Rea D.

10 Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches. Journal of Clinical Oncology 2012; 30(15) Hadji P, Kauka A, Bauer T, Tams J, Hasenburg A, Kieback DG. Effects of exemestane and tamoxifen on hormone levels within the tamoxifen exemestane adjuvant multicentre (TEAM) trial: results of a german substudy. Climacteric : the Journal of the International Menopause Society 2012; 15(5): Hadji P, Kieback DG, Tams J, Hasenburg A, Ziller M. Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. Annals of Oncology 2012; 23(10): Hadji, P., Menschik, T., Kauka, A., Bauer, T., Tams, J., Hasenburg, A., Kieback, D.G.: Effects of exemestane and tamoxifen on hormone levels within the tamoxifen exemestane adjuvant multicentre (TEAM) trial: resulsts of a german, randomized substudy. Climacteric 2012; 15(5): Hanjalic-Beck A, Farthmann J, Hasenburg A. Sexualität der Frau nach onkologischer Therapie. Forum 2012; 27: Klar M, Farthmann J, Bossart M, Stremmel C, Gitsch G, Passlick B, Pache G, Woll J, Hasenburg A. Video-assisted thoracic surgery (VATS) evaluation of intrathoracic disease in patients with FIGO III and IV stage ovarian cancer. Gynecologic Oncology 2012; 126(3): Reinhardt H, Kaiser S, Otte P, Metzke B, Petereit H, Spadaro S, Farthmann J, Rautenberg B, Wilop S, Brummendorf TH, Hasenburg A, Stickeler E, Hug MJ, Schmidt V, Engelhardt M. Multidisciplinary, multicenter chemotherapy surveillance system that efficiently avoids CTx-errors in cancer patients. Onkologie 2012; 35: Scheidt CE, Hasenburg A, Kunze M, Waller E, Pfeifer R, Zimmermann P, Hartmann A, Waller N. Are individual differences of attachment predicting bereavement outcome after perinatal loss? A prospective cohort study. Journal of Psychosomatic Research 2012; 73(5): Schmalfeldt B, Burges A, Hilpert F, Reuss A, Fehm T, Meier W, Kommoss F, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Kommoss S, Ewald- Riegler N, de Gregorio N, Mahner S, Fotopoulou C, Hauptmann S, du Bois A. Disease Progression in female patients with borderline ovarian tumors: Results of the multicentric AGO 'ROBOT' Study. Geburtshilfe und Frauenheilkunde 2012; 72(7): Tautz E, Momm F, Hasenburg A, Guethlin C. Use of Complementary and Alternative Medicine in breast cancer patients and their experiences: A cross-sectional study. European Journal of Cancer 2012; 48(17): van de Water W, Bastiaannet E, Seynaeve C, Markopoulos C, Jones SE, Rea D, Hasenburg A, Putter H, Liefers GJ, van de Velde CJH. Increased breast cancer recurrence in elderly patients is explained by a higher risk of distant recurrence - a TEAM study analysis. European Journal of Cancer 2012; 48: Bossart, M., Beussel, S., Hadji, P., Hasenburg, A.: Frühes Mammakarzinom Lebensqualität nach Switch von Tamoxifen auf Exemestan. Senologie 2012; 9: van de Water W, Markopoulos C, van de Velde CJH, Seynaeve C, Hasenburg A, Rea D, Putter H, Nortier JWR, de Craen AJM, Hille ETM, Bastiaannet E, Hadji P, Westendorp RGJ, Liefers GJ, Jones SE. Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.

11 JAMA 2012; 307(6): Senn, B., Mueller, M., Hasenburg, A., Blankenstein, T., Kammermann, B., Hartmann, A., Donovan, H., Eicher, M., Spirig, R., Engberg, S.: Development of a postsurgical patientreported outcome instrument for women with vulva neoplasie. Oncology Nursing Forum, Vol 39, No.6, November van Hezewijk M, Hille ETM, Putter H, Rea D, Hasenburg A, Markopoulos C, Seynaeve C, van de Velde CJH, Jones SE, Grp TS. Higher risk of locoregional recurrences for women treated with mastectomy compared to breast-conserving therapy in postmenopausal women with early breast cancer treated on the TEAM Trial. European Journal of Cancer 2012; 48: Bartlett JMS, Brookes CL, Piper T, van de Velde CJH, Stocken D, Lyttle N, Hasenburg A, Quintayo MA, Kieback DG, Putter H, Markopoulos C, Kranenbarg EMK, Mallon EA, Dirix LY, Seynaeve C, Rea DW. Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. British Journal of Cancer 2013; 109(9): du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroder W, Münstedt K, Richter B, Kommoss S, Hauptmann S. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. European Journal of Cancer 2013; 49(8): Farthmann J, Hasenburg A, Fotopoulou C, Ewald-Riegler N, Trillsch F, Mahner S, Strauss HG, Wimberger P, Reuss A, du Bois A. Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (Ago) Study Group Robot-Study. International Journal of Gynecological Cancer 2013; 23(8) Fontein DBY, Seynaeve C, Hadji P, Hille ETM, de Water WV, Putter H, Kranenbarg EMK, Hasenburg A, Paridaens RJ, Vannetzel JM, Markopoulos C, Hozumi Y, Bartlett JMS, Jones SE, Rea DW, Nortier JWR, van de Velde CJH. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An International tamoxifen exemestane adjuvant multinational trial analysis. Journal of Clinical Oncology 2013; 31(18): Bossart, M., Peyman, H., Klar, M., Kieback, DG, Hasenburg, A.: Effect of prior chemotherapy regimens on the efficacy of endocrine therapy within a German cohort of the TEAM trial: J Can Res and Clin Oncol, Nov Kaiser S, Reinhardt H, Otte P, Gross B, Spadaro S, Opeker K, Lubrich B, Rautenberg B, Hasenburg A, Stickeler E, Ruch M, Schmidt V, Hug MJ, Duyster J, Engelhardt M. Medication errors in patients with cancer: how an electronic chemotherapy (CTx) management system ensures patient safety and medical error prevention. Onkologie 2013; 36: Lambers K, Farthmann J, Iborra S, Gitsch G, Grosu AL, Henne K, Hasenburg A. Role of intraoperative radiation therapy IORT) in the management of patients with recurrent gynaecological cancer. International Journal of Gynecological Cancer 2013; 23(8) Mayer S, Iborra S, Eltrop S, Steinsiek L, Mahner S, Woelber L, Hasenburg A. Evaluation of sexual functioning and well-being in patients after treatment for gynecological cancer. International Journal of Gynecological Cancer 2013; 23(8).

12 134. Petersen C, Woelber L, Jueckstock J, Neuser P, Hilpert F, De Gregorio N, Hasenburg A, Sehouli J, Habermann A, Mahner S. Adjuvant radio(chemo)therapy in lymph-node positive vulvar cancer - The AGO CaRE-1 study. European Journal of Cancer 2013; 49: van de Water W, Seynaeve C, Bastiaannet E, Markopoulos C, Jones SE, Rea D, Hasenburg A, Putter H, Hille ETM, Paridaens R, de Craen AJM, Westendorp RGJ, van de Velde CJH, Liefers GJ. Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: A tamoxifen exemestane adjuvant multinational atudy analysis. The Oncologist 2013; 18(1): van Hezewijk M, Bastiaannet E, Putter H, Scholten AN, Liefers GJ, Rea D, Hasenburg A, Paridaens R, Hozumi Y, Markopoulos C, Seynaeve C, Jones SE, Marijnen CAM, van de Velde CJH. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the tamoxifen exemestane adjuvant multinational (TEAM) trial. Radiotherapy and Oncology 2013; 108(2): Wagner U, Harter P, Hilpert F, Mahner S, Reuss A, du Bois A, Petru E, Meier W, Ortner P, Konig K, Lindel K, Grab D, Piso P, Ortmann O, Runnebaum I, Pfisterer J, Luftner D, Frickhofen N, Grunwald F, Maier BO, Diebold J, Hauptmann S, Kommoss F, Emons G, Radeleff B, Gebhardt M, Arnold N, Calaminus G, Weisse I, Weis J, Sehouli J, Fink D, Burges A, Hasenburg A, Eggert C. S3-Guideline on diagnostics, therapy and rollow-up of malignant ovarian tumours short version 1.0-AWMF registration number: 032/035OL, June Geburtshilfe und Frauenheilkunde 2013; 73(9): Bossart M, Hadji P, Klar M, Kieback DG, Hasenburg A. Effect of prior chemotherapy regimens on the efficacy of endocrine therapy within a german cohort of the TEAM trial. Journal of Cancer Research and Clinical Oncology 2014; 140(1): Grimm D, Hasenburg A, Steinsiek L, Trillsch F, Mayer S, Eltrop S, Mahner S, Woelber L. Sexual activity and function in patients with gynecological malignancies after completed treatment. Oncology Research and Treatment 2014; 37: Harter P, Kimmig R, de Gregorio N, Reuss A, Pfisterer J, Cibula D, Hilpert F, Meier W, Hanker LC, Canzler U, Sehouli J, Baumann K, Burges A, Gropp-Meier M, Hasenburg A, Belau A, Fehm T, Kosse J, Mahner S, Schmalfeldt B, Marme F, Richter B, Herwig U, Liebrich C, Gerber B, Potenberg J, Krabisch P, Thill M, Merger M, du Bois A. AGO- OVAR 12: A randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy plus /- Nintedanib for advanced ovarian cancer. Oncology Research and Treatment 2014; 37: Duveken BY Fontein, Seynaeve, C., Peyman, H., Hille, E., van de Water, W., Putter, H., Meershoek-Klein Kranenbarg, E., Hasenburg, A., Parideans, R., Vannetzel, J.-M., Markopoulos, C., Hozumi, Y., Bartlett, J., Jones, S., Rea, D., Nortier, J., van de Velde, C.: Specific adverse events predict survival benefit in patients treated with Tamoxifen or aromatase inhibitors: An international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 2014, 18; Hillemanns P, Wolber L, Juckstock J, Neuser P, Hilpert F, Harter P, De Gregorio N, Hasenburg A, Sehouli J, Habermann A, Fuerst ST, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, Du Bois A, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Petersen C, Mahner S. AGO Vulva CaRE-1 multicenter study - adjuvant radio(chemo)therapy in vulvar cancer. Oncology Research and Treatment 2014; 37: Sabine VS, Crozier C, Brookes CL, Drake C, Piper T, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea DW, Bartlett JMS. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational

13 pathology study. Journal of Clinical Oncology 2014; 32(27): Trillsch F, Mahner S, Rutzel JD, Vettorazzi E, Reuss A, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Klaus B, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroder W, Munstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Fehm T, Meier W, Ewald-Riegler N, De Gregorio N, Hilpert F, Du Bois A. Prognostic impact of the time interval between primary and re-staging surgery in patients with borderline ovarian tumours (BOT): An analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group. Oncology Research and Treatment 2014; 37: Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver- Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Annals of Oncology 2014; 25(7): Bossart, M., Hasenburg, A.: Nachsorgeuntersuchungen bei gynäkologischen Malignomen. Gynäkologe 2014, 47: Lambers, K., Hasenburg, A., Stickeler, E., Gitsch, G., Grosu, A.L., Henne, K., Farthmann, J.: The need for intraoperative radiation therapy in the management of patients with recurrent gynaecological cancer. European Journal of Gynaecological Oncology Haug, S., Schnerch, D., Halbach, S., Mastroianni, J., Dumit, VI,Follo, M., Hasenburg, A., Köhler, M., Dierbach, H., Herzog, S., Proske, A., Werner, M., Dengjiel, J., Brummer, T., Laßmann, S., Wäsch, R., Zeiser, R.: Metadherin exon 11 skipping variant enhancesmetastatic spread of ovarian cancer. International Journal of Cancer 2014(58) Farthmann J, Hasenburg A, Weil M, Fotopoulou C, Ewald-Riegler N, du Bois O, Trillsch F, Mahner S, Strauss HG, Wimberger P, Reuss A, du Bois A. Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) study group ROBOT study. supportive care in cancer : Official Journal of the Multinational Association of Supportive Care in Cancer 2015; 23(1): Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K, Keyver-Paik M, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Ewald-Riegler N, de Gregorio N, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss H, Hellriegel M, Wimberger P, Kommoss S, Kommoss F, Hauptmann S, du Bois A. Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study. British Journal of Cancer Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel LF, Woelber L: Adjuvant therapy in lymph nodepositive vulva cancer: The AGO-CaRE-1 Study. Journal of the National Cancer Institute 2015, 107(3).

14 Übersichtsartikel 1. Hasenburg, A., Spätling, L.: Vorzeitige Wehentätigkeit - Ursachen und Therapiemöglichkeiten. TW Gynäkologie 1996(9), Hasenburg, A., Kieback, D.G.: Gestationsbedingte Trophoblasterkrankungen eine Übersicht. Der Frauenarzt 1997(38), Spätling, L., Hasenburg, A.: Fruchtwasserembolie. Gynäkologe 1997(10), Hasenburg, A., Grothey, A., Kieback, D.G.: Aktuelle Studien zur Therapie des Zervixkarzinoms in den USA. Der Onkologe 1998(4), Grothey, A., Düppe, J., Hasenburg, A., Voigtmann, R.: Anwendung alternativmedizinischer Methoden durch onkologische Patienten. Dtsch. med. Wschr.1998(123), Hasenburg, A., Fischer, D.-C., Kieback, D.G.: Aktuelle Studien zur Therapie des Zervixkarzinoms in den USA. Der Onkologe 2001(7), Hasenburg, A., Watermann, D.: Sexualität und Lebensqualität bei Frauen mit ungewolltem Harnverlust. Praktische Gynäkologie 2002(6), Hasenburg, A., Watermann, D.: Inkontinenz, Sexualität und Lebensqualität. Z. f. Physiotherapeuten 2002(54), Watermann, D., Hasenburg, A.: Physiologie und Pathophysiologie von Harnspeicherung und Entleerung: Neue Ansätze zum Verständnis eines multifaktoriellen Systems. Z.f. Physiotherapeuten 2002(54), Watermann, D., Hasenburg, A.: Das spannungsfreie Vaginalband: Ein neues operatives Verfahren zur Therapie der weiblichen Stress-Harninkontinenz. Z. f. Physiotherapeuten 2002(54), Hasenburg, A., D.O. Watermann, M. Orlowska-Volk, G. Gitsch: Pseudomyxoma peritonei. ISSN (online). European Clinics in Obstetrics and Gynaecology 2005(1), Hasenburg, A.: Komplexes Geschehen. Die operative Therapie des frühen und fortgeschrittenen Ovarialkarzinoms. Gynäkologische Nachrichten 2005(6), Scheidt, C. E., Waller, N., Wangler, J., Hasenburg, A.: Trauerverarbeitung nach Prä- und Perinatalverlust, Prävalenz, klinisches Bild und Behandlung eine Übersicht über den aktuellen Forschungsstand. Psychotherapie Psychosomatik Medizinische Psychologie 2007(57): du Bois, A., Burger, A., Emons, G., Fink, D., Gropp, M., Harter, P., Hasenburg, A., Hauptmann, S., Jäger, W., Kimmig, R., Kommoss, F., Kreienberg, R., Kuhn, W., Meier, W., Münstedt, K., Ortmann, O., Pfisterer, J., Richter, B., Runnebaum, I., Schmalfeldt, B., Schröder, W., Sehouli, J., Tanner, B., Wagner, U.: S2k-Leitlinie maligne Ovarialtumoren. Update 2008 zu Diagnostik und Therapie, Gynäkologie + Geburtshilfe 2008(2), Hasenburg, A., Schröck, R., Schmalfeldt, B., Ortmann, O.: Nachsorge und Rehabilitation (nach Therapie eines Ovarialkarzinoms). Der Onkologe 2008; 14(11): Hasenburg, A., Gabriel, B., Einig, E.-M.: Sexualität nach Therapie eines Ovarialkarzinoms. Geburtsh Frauenheilkunde 2008(68): 1-4

15 17. Kurzeder, Ch. (Reviewer: Meier, W., Hasenburg, A.): Keimzell- und Keimstrang-Stroma- Tumoren des Ovars. CME praktische Fortbildung, Gynäkologie, Geburtsmedizin und Gynäkologische Endokrinologie 2008(2), Hadji, P., Asmar, L., van Nes, J.G., Menschik, T., Hasenburg, A., Kuck, J., Nortier, J.W.R., van de Velde, C.J.H., Jones, S.E., Ziller, M.: The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multination (TEAM) trial: a metaanalysis of the US, German, Netherlands and Belgium sub-studies. 19. Hasenburg, A., Farthmann, J., Hanjalic-Beck, A.: Tabuthema Sexualität nach der Therapie. ÄP Gynäkologie 2010, Hasenburg, A., Rautenberg, B.: Gynäkologische Krebserkrankungen in der Schwangerschaft. Der Onkologe 2012, 18(4): Hanjalic-Beck, A., Farthmann, J., Hasenburg, A.: Sexualität der Frau nach onkologischer Therapie. Forum 2012, 27: Hasenburg, A., Gessner, C.: Erfülltes Sexualleben auch mit Krebs. Medical Tribune, Nr. 3, Mai Tautz, E., Momm, F., Hasenburg, A., Guethlin, C.: Use of complementary and alternative medicine in patients and their experiences: A cross-sectional study. European Journal of Cancer, Avalilable online 5/ Hasenburg, A., Farthmann, J., Hanjalic-Beck, A.: Liebe nach der Krebsdiagnose. Georg Thieme Verlag KG, XX Die Zeitschrift für Frauen in der Medizin, ) Buchbeiträge 1. Hasenburg, A., Jaspers, V., Abdallah, A., Fallenstein, F., Spätling, L.: Welche Faktoren beeinflussen das Therapieregime? Ergebnisse einer Umfrage zur Tokolyse. In: Bolustokolyse in Theorie und Praxis , Steinkopff Verlag Darmstadt, Hasenburg, A., Siegmund-Schultze, E., Fallenstein, F., Spätling, L.: Theorien zur Entstehung uteriner Kontraktionen. In: Bolustokolyse in Theorie und Praxis 73-77, Steinkopff Verlag Darmstadt, Danders, R., Hasenburg, A., Fallenstein, F., Spätling, L.: Vierkanaltokographie unter der Geburt In: Bolustokolyse in Theorie und Praxis 79-83, Steinkopff Verlag Darmstadt, Behrens, C., Hasenburg, A., Steffens, J., Fallenstein, F., Spätling, L.: Vierkanaltokographie bei vorzeitiger Wehentätigkeit In: Bolustokolyse in Theorie und Praxis 85-90, Steinkopff Verlag Darmstadt, Jaspers, V., Hasenburg, A., Behrens, C., Abdahllah, A., Spätling, L.: Durchführung der Tokolyse heute - Ergebnisse einer Umfrage. In: Bolustokolyse in Theorie und Praxis , Steinkopff Verlag Darmstadt, Fallenstein, F., Hasenburg, A., Jaspers, V., Spätling, L.: Derzeitiger Stand der Tokolysetherapie. Ergebnis einer bundesweiten Umfrage. Sonderdruck aus: Standortbestimmung der Tokolysebehandlung. Hrsg F. Wolff, Steinkopff Darmstadt, Pflege heute. Lehrbuch und Atlas für Pflegeberufe. Schwangerschaft, Geburt und Wochenbett (Kapitel 12). Pflege in der Gynäkologie (Kapitel 32), Gustav Fischer Verlag Ulm, Stuttgart, Jena, Lübeck, Hrsg.: Baumgartner, L., Kirstein, R., Möllmann, R.

16 8. Altenpflege konkret. Gesundheits- und Krankheitslehre. Erkrankungen der Geschlechtsorgane Urban & Fischer Verlag München, Jena, Naturheilpraxis Heute. Lehrbuch und Atlas. Elvira Bierbach: Geschlechtsorgane (Kapitel 17). Schwangerschaft, Geburt, Stillzeit (Kapitel 27), Urban & Fischer Verlag München, Jena, 2000, Hrsg.: Bierbach, E. 10. Spätling, L., Hasenburg, A.: Fruchtwasserembolie. In: Schneider, H., Husslein, P., Schneider, K.T.M. (Hrsg.) Geburtshilfe, , Springer-Verlag Berlin, Heidelberg, New York, Kieback, D.G., Tong, X.-W., Hasenburg, A., Runnebaum, I.B.: Gentherapie des Ovarialkarzinoms. In: Kaufmann, M., Scharl., A., Ahr, A. (Hrsg.) Gynäkologie und Geburtshilfe Frankfurt 2000, sympomed München Kieback DG., Hasenburg A., Tong XW, Runnebaum IB, Fischer D-C.: Gene therapy of ovarian cancer - state of the art and future perspectives. in: Altchek A, Deligdisch L, Kase N (eds.), Diagnosis and Management of ovarian disorders. Part 2B, chapter 21, p , 2nd edition, 2003, Elsevier Science 13. Hanjalic-Beck, A., Leiber, C., Hasenburg, A.: Fertilität und Sexualität.Supportivtherapie in der Onkologie, Urban & Vogel, 2009: Farthmann, J., Hasenburg, A.: Sexuality after ovarian cancer therapy. Ovarian Cancer- Clinical and Therapeutic Perspectives 2012; Kapitel 16, Farthmann, J., Schwab, R., Hasenburg, A.: ESMO Handbook: Rehabilitation Issues During Cancer Treatment and Follow Up. Sectio I. How to deal with physical/psychological complaints during treatment and follow up. Chapter 9. Sexuality/reproductive issues. September 2014